fbpx

Belviq Weight Loss Drugs Withdrawn Without Compensation Class Action

On its first presentation to the Food and Drug Administration (FDA) for approval, the weight-loss drug Belviq was rejected. After some additional studies, it was accepted by the FDA in 2012. This class action brings suit against Eisai, Inc. and Arena Pharmaceuticals over Belviq and Belviq XR, alleging that the companies knew the drugs increase the consumers’ risk of cancer, and that the companies did not give any compensation to those who had bought the drugs and had to stop taking them when they were withdrawn from the market.

The class for this action is all persons in the US who bought Belviq or Belviq XR.

The active ingredient in the Belviq drugs is lorcaserin. In 2007, Arena’s studies showed that lorcaserin caused aggressive tumors in rats. Although the data later showed a decline in tumors, Arena was unable to explain it, and the FDA did not approve the drug.

However, after what the complaint calls “questionable additional studies,” Arena resubmitted its application and it was approved. However, the complaint notes that the drug was accepted “with restrictions, namely that it could only be used for adults with a body mass index (‘BMI’) greater than 30, or those with a BMI of 27 or more who have at least one weight-related condition.”

Additional long-term studies were also required for cardiovascular risks. However, the complaint alleges that “this study ended up resurfacing the cancer concerns that Arena knew about from when [it] began the research in 2007…”

Belviq was launched in the US in 2012, with Arena handling manufacturing and Eisai having exclusive rights to “commercialize lorcaserin” in the US and, eventually, elsewhere.

The complaint alleges that Eisai “was aware of the cancer concerns regarding the Belviq Medications as early as 2012” but that it “aggressively marketed” them to doctors and consumers. In 2013, it increased the number of sales representatives it used to market the drugs.

According to the complaint, Eisai “knowingly and affirmatively marketed the defective Belviq Medications … using knowingly false information regarding the Products’ efficacy and safety…” They were marketed both to doctors and directly to consumers.

The FDA requested the withdrawal of the drugs in 2020 because of “increased occurrence of cancer” in the clinical trials.

The complaint alleges, “The safety risks of the Belviq Medications are not mere conjecture; to date, multitudes of individuals have brought personal injury lawsuits related to their purchase and use of the Belviq Medications…”

This current class action is not about personal injury. Instead, it asks that those who bought the drugs should recover what they spent on them.

The counts include breach of the implied warranty of merchantability, violation of consumer fraud laws, and unjust enrichment.

Article Type: Lawsuit
Topic: Consumer

Most Recent Case Event

Belviq Weight Loss Drugs Withdrawn Without Compensation Complaint

November 11, 2021

On its first presentation to the Food and Drug Administration (FDA) for approval, the weight-loss drug Belviq was rejected. After some additional studies, it was accepted by the FDA in 2012. This class action brings suit against Eisai, Inc. and Arena Pharmaceuticals over Belviq and Belviq XR, alleging that the companies knew the drugs increase the consumers’ risk of cancer, and that the companies did not give any compensation to those who had bought the drugs and had to stop taking them when they were withdrawn from the market.

Belviq Weight Loss Drugs Withdrawn Without Compensation Complaint

Case Event History

Belviq Weight Loss Drugs Withdrawn Without Compensation Complaint

November 11, 2021

On its first presentation to the Food and Drug Administration (FDA) for approval, the weight-loss drug Belviq was rejected. After some additional studies, it was accepted by the FDA in 2012. This class action brings suit against Eisai, Inc. and Arena Pharmaceuticals over Belviq and Belviq XR, alleging that the companies knew the drugs increase the consumers’ risk of cancer, and that the companies did not give any compensation to those who had bought the drugs and had to stop taking them when they were withdrawn from the market.

Belviq Weight Loss Drugs Withdrawn Without Compensation Complaint
Tags: Cancer Risk, Fraud, Pharmaceuticals